Skip to main content

An update on TroVax for the treatment of progressive castration-resistant prostate cancer.

Publication ,  Journal Article
Abern, M; Kaufman, HL; Latchamsetty, K
Published in: Onco Targets Ther
2011

Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax(®)) vaccine.

Duke Scholars

Published In

Onco Targets Ther

DOI

EISSN

1178-6930

Publication Date

2011

Volume

4

Start / End Page

33 / 41

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Abern, M., Kaufman, H. L., & Latchamsetty, K. (2011). An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther, 4, 33–41. https://doi.org/10.2147/OTT.S14271
Abern, Michael, Howard L. Kaufman, and Kalyan Latchamsetty. “An update on TroVax for the treatment of progressive castration-resistant prostate cancer.Onco Targets Ther 4 (2011): 33–41. https://doi.org/10.2147/OTT.S14271.
Abern M, Kaufman HL, Latchamsetty K. An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther. 2011;4:33–41.
Abern, Michael, et al. “An update on TroVax for the treatment of progressive castration-resistant prostate cancer.Onco Targets Ther, vol. 4, 2011, pp. 33–41. Pubmed, doi:10.2147/OTT.S14271.
Abern M, Kaufman HL, Latchamsetty K. An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther. 2011;4:33–41.

Published In

Onco Targets Ther

DOI

EISSN

1178-6930

Publication Date

2011

Volume

4

Start / End Page

33 / 41

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis